THE SCIENCE
KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). Research has primarily examined KPV in relation to inflammatory signaling, intestinal inflammation, and cellular responses.
MOLECULAR STRUCTURE
KPV consists of three amino acids: lysine, proline, and valine. It represents the C-terminal tripeptide sequence of α-MSH and has been investigated as a distinct peptide in experimental inflammation research.
PEPT1 TRANSPORT
Experimental research has shown that KPV can be transported into intestinal epithelial and immune cells through the human peptide transporter PepT1. This transport mechanism has been investigated as part of KPV's effects on intracellular inflammatory signaling.
NF-κB & MAPK SIGNALING
Studies in human cell models have examined KPV's effects on NF-κB and MAPK inflammatory signaling pathways. Experimental treatment reduced activation of these pathways and was associated with lower production of certain pro-inflammatory cytokines.
INTESTINAL INFLAMMATION
- KPV has been studied in experimental models of intestinal inflammation. In one study, KPV reduced inflammatory markers in cell experiments and reduced disease-associated inflammatory responses in mouse models of colitis.
PRECLINICAL RESEARCH
The evidence base relevant to TB-500 is predominantly preclinical. Findings from laboratory and animal studies should not be assumed to demonstrate the same effects in humans, and research involving thymosin beta-4 should not automatically be interpreted as evidence for every TB-500 preparation.
PRECLINICAL RESEARCH
The available evidence for KPV is predominantly preclinical. Findings from cell and animal studies should be interpreted according to the experimental model, study design, and specific endpoints measured and should not automatically be assumed to demonstrate the same effects in humans